Announcements Trials
Browse Landscape

Phase

Phase 1 5

Status

Completed 4Active not recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Conditions

Multiple Myeloma 11Lymphoma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Neoplasm Metastasis 9Leukemia 9Neoplasms 8Myelodysplastic Syndromes 8Hodgkin Disease 8Carcinoma, Non-Small-Cell Lung 8Breast Neoplasms 8Lymphoma, Non-Hodgkin 7Leukemia, Myeloid, Acute 7Carcinoma, Renal Cell 7Prostatic Neoplasms 6Melanoma 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Recurrence 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hematologic Neoplasms 5Graft vs Host Disease 5Advanced Cancer 5Unspecified Adult Solid Tumor, Protocol Specific 4Primary Myelofibrosis 4Pancreatic Neoplasms 4Neoplasms, Plasma Cell 4Myeloproliferative Disorders 4Lung Neoplasms 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Myeloid, Chronic-Phase 4Glioblastoma 4

Interventions

Nivolumab 8Paclitaxel 6Sirolimus 5Bevacizumab 5temsirolimus 4Pemetrexed 4Ipilimumab 4Docetaxel 4Carboplatin 4ARRY-334543 4Gemcitabine 3Erlotinib Hydrochloride 3olaparib 2linrodostat 2apatinib 2anlotinib 2abemaciclib 2Vorinostat 2Sunitinib 2Magnetic Resonance Spectroscopy 2Irinotecan 2Everolimus 2Doxorubicin 2Dasatinib 2Chlorogenic Acid 2Cetuximab 26-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline 2vorolanib 1vistusertib 1trametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × Advanced Cancer × Sirolimus × Clear all
NCT01087554 2026-01-16

Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
249 enrolled

Advanced Cancer

NCT00940381 2015-11-18

Sirolimus and Cetuximab in Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Completed
165 enrolled

Advanced Cancer

NCT01054313 2015-10-07

Docetaxel and Sirolimus in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Completed
103 enrolled

Advanced Cancer

NCT00707135 2014-01-17

Rapamycin in Advanced Cancers

University of Chicago

Phase 1 Completed
40 enrolled

Advanced Cancer

NCT00708591 2014-01-17

Study of Rapamycin Plus Ketoconazole in Advanced Cancers

University of Chicago

Phase 1 Completed
57 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡